Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23376737 | 0.89 | MAP3K14 (0.36) | SLC6A4SLC6A3ESR1ESR2KDM4C | |
| SCHEMBL22532060 | 0.80 | MAP3K14 (0.38) | ESR1ESR2 | |
| SCHEMBL29828611 | 0.80 | MAP3K14 (0.38) | ESR1ESR2 | |
| SCHEMBL23364873 | 0.80 | MAP3K14 (0.38) | ESR1ESR2 | |
| SCHEMBL30496896 | 0.80 | MAP3K14 (0.38) | ESR1ESR2 | |
| SCHEMBL17441186 | 0.79 | KDM1A (0.33) | KDM1A | |
| SCHEMBL29310262 | 0.78 | DRD2 (0.35) | ESR1ESR2 | |
| SCHEMBL17441194 | 0.76 | KDM1A (0.34) | KDM1A | |
| SCHEMBL29310253 | 0.76 | DRD2 (0.33) | KDM1A | |
| SCHEMBL17441664 | 0.75 | CYP2C19 (0.30) | ESR1ESR2KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577367-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577367-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
| US-10246456-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246456-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246456-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | SLC6A4 4250/4885SLC6A3 4820/4885ESR1 2130/4885 |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | SLC6A4 4250/4885SLC6A3 4820/4885ESR1 2130/4885 |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | SLC6A4 4133/4885SLC6A3 4816/4885ESR1 2183/4885 |
| US-10577367-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | SLC6A4 4133/4885SLC6A3 4816/4885ESR1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.